Scarica l'app Stockscreener
35.56
0.87%
0.305
Dopo l'orario di chiusura:
35.56
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CSTL Giù?
Forum
Previsione
Precedente Chiudi:
$35.26
Aprire:
$35.56
Volume 24 ore:
167.72K
Relative Volume:
0.43
Capitalizzazione di mercato:
$1.09B
Reddito:
$339.92M
Utile/perdita netta:
$-12.83M
Rapporto P/E:
-82.79
EPS:
-0.4295
Flusso di cassa netto:
$4.52M
1 W Prestazione:
-0.70%
1M Prestazione:
+6.40%
6M Prestazione:
+43.16%
1 anno Prestazione:
+59.96%
Intervallo 1D:
$34.75
$35.92
Intervallo di 1 settimana:
$34.14
$36.99
Portata 52W:
$17.72
$44.28
Castle Biosciences Inc Stock (CSTL) Company Profile
Nome
Castle Biosciences Inc
Settore
Industria
Telefono
866-788-9007
Indirizzo
1500 W. PARKWOOD AVE., FRIENDSWOOD, TX
Compare CSTL vs TMO, DHR, NTRA, A, IQV
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
35.56 | 1.09B | 339.92M | -12.83M | 4.52M | -0.4295 |
TMO
Thermo Fisher Scientific Inc
|
654.80 | 249.58B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
214.06 | 157.81B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
410.35 | 59.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
167.78 | 48.71B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
258.21 | 44.50B | 16.63B | 1.39B | 2.12B | 8.0674 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2021-04-30 | Iniziato | Lake Street | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | Reiterato | Canaccord Genuity | Buy |
| 2019-08-19 | Iniziato | BTIG Research | Buy |
| 2019-08-19 | Iniziato | Canaccord Genuity | Buy |
| 2019-08-19 | Iniziato | Robert W. Baird | Outperform |
| 2019-08-19 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Castle Biosciences Inc Borsa (CSTL) Ultime notizie
Bank of America Corp DE Makes New $2.35 Million Investment in Castle Biosciences, Inc. $CSTL - MarketBeat
Precision Trading with Castle Biosciences Inc. (CSTL) Risk Zones - Stock Traders Daily
Low-risk melanoma patients who skipped lymph node biopsy had 99.6% recurrence-free survival at five years. - Stock Titan
Castle Biosciences (CSTL) Study Validates TissueCypher Test's Im - GuruFocus
A test changed doctors’ plans for 90% of patients with the same precancerous esophagus condition. Their risks differed. - Stock Titan
Castle Biosciences CEO sells $512k in stock - Investing.com
Form 4 Castle Biosciences Inc For: 26 September By Investing.com - Investing.com Nigeria
Castle Biosciences (NASDAQ:CSTL) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Texas bioscience firm expands in Scottsdale as AZ headcount tops 200 - The Business Journals
New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™ - PR Newswire
Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 8,580 Shares - MarketBeat
CSTL Looks 17.2% Overvalued on GF Value™ as Market Prices in Str - GuruFocus
Castle Biosciences opens 55,000 sq ft Arizona lab facility By Investing.com - Investing.com Canada
Castle Biosciences to Open New Lab in Arizona - marketscreener.com
Castle Biosciences opens 55,000 sq ft Arizona lab facility - Investing.com
Castle Biosciences,Opens New Laboratory And Office Facility In Scottsdale, Arizona - TradingView
Castle Biosciences to Open New Laboratory Facility in Scottsdale - PR Newswire
Castle Biosciences (CSTL) Insider Trading Activity 2026 $CSTL - MarketBeat
Castle Biosciences, Inc. (CSTL) Stock Analysis: A 19.63% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Castle Biosciences Inc (CSTL) Shares Surge 3.7% -- What GF Score of 82 Tells Investors - GuruFocus
Castle Biosciences (NASDAQ: CSTL) Chief Commercial Officer Juvenal Tobin W Sells 6,600 Shares Between $32.32 and $35.14 - Kalkine Media
Castle Biosciences Q2 2026 Earnings: Narrower-Than-Expected Loss Drives Modest Stock GainEstimate Uncertainty - siam.in
Castle Biosciences (CSTL) Chief Commercial Officer Tobin Juvenal Sells 6,600 Shares - GuruFocus
Tobin Juvenal Sells 3,306 Shares of Castle Biosciences (NASDAQ:CSTL) Stock - marketbeat.com
Castle Biosciences (NASDAQ:CSTL) Insider Sells 3,294 Shares of Stock - MarketBeat
6,600 Castle Biosciences (CSTL) shares sold under preset 10b5-1 plan - Stock Titan
Castle Biosciences (NASDAQ:CSTL) Shares Up 4.3%Here's What Happened - MarketBeat
Castle Biosciences TissueCypher Study Shows Improved Risk-Aligned Barrett’s Esophagus Management - Yahoo Finance
CSTL Looks 12.1% Overvalued on GF Value™ - GuruFocus
A study found a test could nearly double closer monitoring or treatment for some Barrett’s patients - Stock Titan
Castle Biosciences (CSTL) CCO plans more stock sales under 10b5-1 plan - Stock Titan
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Preset sale plan at Castle Biosciences (CSTL) covers 29K shares - Stock Titan
Castle Biosciences, Inc.JAAD Publication Shows Improved Performance of DecisionDx-SCC - marketscreener.com
Responsive Playbooks and the CSTL Inflection - Stock Traders Daily
Castle Biosciences, Inc. (CSTL) Stock Price Quote Today & Current Price Chart - Capital.com
JAAD Publication Shows Improved Performance of DecisionDx®-SCC - STLtoday.com
SciBase receives additional order from Castle Biosciences, advancing the collaboration - Yahoo Finance
Bank of New York Mellon Corp Invests $2.34 Million in Castle Biosciences, Inc. $CSTL - MarketBeat
Castle Biosciences Stock Price Forecast. Should You Buy CSTL? - StockInvest.us
Castle Biosciences Inc. (CSTL) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Castle Biosciences, Inc. $CSTL Shares Sold by Bank of America Corp DE - MarketBeat
Castle Biosciences COO Oelschlager sells $138,642 in shares By Investing.com - Investing.com Nigeria
Castle Biosciences COO Oelschlager sells $138,642 in shares - investing.com
Castle Biosciences CCO Tobin Juvenal sells $51,190 in shares By Investing.com - Investing.com South Africa
Castle Biosciences (NASDAQ:CSTL) Beats Estimates As Momentum Builds - Kalkine Media
Castle Biosciences (CSTL) Chief Commercial Officer Tobin Juvenal Sells 1,730 Shares - GuruFocus
Castle Biosciences (CSTL) Slips 2.4% to $32.62: Key Support in FocusNews Sentiment - vinanet.vn
Castle Biosciences CCO Tobin Juvenal sells $51,190 in shares - Investing.com
Empowered Funds LLC Acquires New Shares in Castle Biosciences, Inc. $CSTL - marketbeat.com
Castle Biosciences (NASDAQ: CSTL) CCO sells 1,730 shares under 10b5-1 plan - Stock Titan
Castle Biosciences Inc Azioni (CSTL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Castle Biosciences Inc Azioni (CSTL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Sep 21 '26 |
Sale |
35.33 |
8,580 |
303,166 |
21,479 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Sep 21 '26 |
Sale |
35.33 |
5,916 |
209,036 |
9,550 |
| Juvenal Tobin W | Chief Commercial Officer |
Sep 15 '26 |
Sale |
35.14 |
3,294 |
115,758 |
58,584 |
| Juvenal Tobin W | Chief Commercial Officer |
Sep 14 '26 |
Sale |
32.32 |
3,306 |
106,863 |
61,878 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Sep 11 '26 |
Option Exercise |
2.39 |
8,584 |
20,516 |
30,063 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Sep 11 '26 |
Sale |
32.02 |
8,584 |
274,862 |
21,479 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Sep 11 '26 |
Sale |
32.02 |
5,934 |
190,008 |
12,268 |
0.97%
0.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):